Bond, Michael J.; Chu, Ling; Nalawansha, Dhanusha A.; Li, Ke; Crews, Craig
ChemRxiv, 2020
DOI: https://doi.org/10.26434/chemrxiv.12091176.v1
We report the development of LC-2, the first PROTAC capable of degrading endogenous KRASG12C. LC-2 covalently binds KRASG12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRASG12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRASG12C cell lines. LC-2 demonstrates that PROTAC-mediated degradation is a viable option for attenuating oncogenic KRAS levels and downstream signaling in cancer cells.
A blog highlighting recent publications in the area of covalent modification of proteins, particularly relating to covalent-modifier drugs. @CovalentMod on Twitter, @covalentmod@mstdn.science on Mastodon, and @covalentmod.bsky.social on BlueSky
Fragment-Based Covalent Targeting of Lysines at the Allosteric Latch Site of SHP2.
Vincenzo Di Lorenzo , Noémi Csorba , Renáta Szabó , Levente Kollár , Yvette Roske , Ivan Rand̵elović , Krisztina Balázs , Tibor Vikt...
-
Xu-liang Xu, Ti-ti Ying, Xiao-wen Wu, Yun-jun Chen, Gang-ao Hu, Yu-tian Guan, Shi-yi Liu, He Wang, Mohamed Seif, Mahmoud Emam, Hong Wang, We...
-
Joseph E Klebba, Nilotpal Roy, Steffen M Bernard, Stephanie Grabow, Melissa A. Hoffman, Hui Miao, Junko Tamiya, Jinwei Wang, Cynthia Berry, ...
-
Lavleen K. Mader, Namita Maunick, Jessica E. Borean, Jeffrey W. Keillor RSC Med. Chem. , 2025 https://doi.org/10.1039/D5MD00777A Human tissu...
